INNOVATIVE INDUSTRIAL PROPERTIES INC Q3 FY2026 earnings call

• Life Science Diversification: Executed a $245 million mezzanine loan commitment to IQHQ for the Alewife Park campus in Cambridge, MA, with an additional $30 million preferred equity investment. Total committed exposure to IQHQ is now approximately $545 million. These investments are projected to account for ~26% of total annualized income upon full funding, targeting an average interest rate of ~15.8%.
• Leasing Momentum: Achieved record leasing activity with 604,000 square feet executed across six properties in Q3, plus an additional 270,000 square feet subsequent to quarter-end in Pennsylvania. Year-to-date gross leasing activity totals ~1.3 million square feet across 12 properties (15% of the portfolio).
• Portfolio Recovery: Regained possession of properties previously leased to Parallel, PharmaCann, and The Cannabis Company. Re-tenanting efforts are progressing, with new tenants such as Vireo installed at Battle Green and active pipelines for 4Front Ventures assets.
• Capital Markets Access: Completed a $54 million public offering of 9.25% Series B Preferred Stock post-quarter end to fund the Alewife Park mezzanine loan. Extended the $87.5 million revolving credit facility maturity to January 2027.
• Financial Strength: Maintained strong liquidity of $142 million at quarter-end (excluding the new preferred raise). Net debt to adjusted EBITDA remained low at 2.1x, and net debt to total gross assets stood at 19%.
• Industry Environment: Federal cannabis rescheduling proceedings continue, potentially improving operator economics. State-level milestones include Florida approving 22 new medical licenses and Massachusetts surpassing $10 billion in cumulative adult-use sales.

The company reported total revenues of $64.9 million for the third quarter, a sequential increase from $63.3 million in Q2. This growth was driven by new lease executions and recoveries of past due rents, primarily from Battle Green, which contributed $0.15 per share to results. Adjusted Funds From Operations (AFFO) totaled $54.8 million, or $1.96 per diluted share, up 7% sequentially from $53 million ($1.83 per share) in the prior quarter. Interest and other income reached $14.3 million, including $10.4 million from life science financial investments in IQHQ. The cannabis portfolio remains the primary revenue driver, with significant leasing activity across California, Massachusetts, New York, Ohio, and Washington, while life science investments are expected to provide increasing accretive income as the Alewife Park project stabilizes.

• Management did not provide specific forward-looking financial guidance for AFFO or revenue per share.
• Expressed confidence in continued accretive growth from life science investments, noting that the fourth quarter will reflect a larger beneficial impact from the Alewife Park investment than the third quarter.
• Indicated that the remaining $134 million of the initial $245 million Alewife mezzanine loan is expected to be funded through the fourth quarter of 2027.
• Highlighted an opportunity to acquire an additional $155 million tranche of the IQHQ mezzanine loan from another lender if capital access permits and it remains accretive.

• Regulatory Uncertainty: Federal marijuana rescheduling outcomes remain uncertain, though potential reform could benefit operators.
• Lease Execution Risk: Agreements for 446,000 square feet (Colorado and Washington properties) are subject to licensing transfers and regulatory approvals, with no assurance of final execution.
• Tenant Credit Quality: Past performance has relied on recovering past-due rents and security deposits from defaulted tenants; however, most security deposits for five listed tenants are exhausted, leaving limited buffer for non-paying entities.
• Concentration Risk: While diversifying into life sciences, a significant portion of current vacancy (~2/3) relates to two Florida assets formerly leased to Parallel, creating market-specific concentration risk despite positive Florida sales trends.

Q: Analyst asked about the timeline for re-leasing recently vacated properties (Parallel, PharmaCann, etc.) and whether AFFO can sustain above the dividend payout given reliance on one-time rent recoveries. / A: Ben Regin noted historical re-tenancy timelines range from 6 to 18 months due to regulatory processes but expressed optimism, particularly for Florida assets where sales records were set. David Smith acknowledged the strong Q3 result drove the payout ratio down to 97% and highlighted the company's historical success in recovering past-due rents, though he avoided providing specific forward guidance on sustaining AFFO levels above dividends without these one-time benefits.

Q: Analyst inquired if the record Q3 leasing volume resulted from delayed deals closing simultaneously or accelerated demand, and how sustainable this velocity is. / A: Ben Regin attributed the volume to both factors, describing real estate transactions as "chunky" with several deals converging in Q3. He cited increased M&A activity and operator optimism as drivers for sustained demand. He emphasized that the remaining vacancy is heavily concentrated in two Florida assets (formerly Parallel), which are well-positioned due to strong local market performance and recent license approvals.

Q: Analyst questioned the rationale behind the additional $30 million preferred equity investment in IQHQ and whether it reflected better execution or cost overruns compared to initial underwriting. / A: Alan D. Gold explained that IQHQ’s performance has improved, evidenced by higher leasing activity at Alewife Park (78% leased) and emerging demand in other markets like San Diego. The additional capital was deployed because it represented a highly accretive opportunity with attractive pricing, aligning with IIP’s strategy to capitalize on high-quality life science assets rather than being driven by unexpected cost increases.

Q: Analyst asked about the likelihood of IIP acquiring the incremental $155 million tranche of the IQHQ mezzanine loan and the Board’s stance on maximum investment limits in IQHQ. / A: Alan D. Gold stated that acquiring the extra tranche is part of their agreement and likely if capital access allows, describing it as very accretive. Regarding limits, he indicated the Board views these investments as a vehicle for broader life science diversification beyond just IQHQ. Since diversification has successfully improved access to new lenders and capital sources, the Board would consider further incremental investments if opportunities arise that support this strategic goal.